CME Information
TARGET AUDIENCE
This educational activity is intended for medical oncology physicians, nurses, and other members of the health care team who care for patients with mCRC.
PROGRAM OVERVIEW
This activity will provide guidance on how to develop practical biomarker testing protocols and identify appropriate therapeutics treatments for patients in all stages of mCRC.
Upon completion of this activity, the learners should be able to:
- Apply the latest guideline recommendations regarding biomarker testing in mCRC
- Describe when biomarker testing should be performed, including the process/protocols and the role of the multidisciplinary team
- Explain the need for biomarker testing to guide individualized therapy decisions to their colleagues and patients
- Review targeted therapeutic options for the treatment of mCRC and identify their utilization in appropriate patients
- Describe the role of mCRC care team members and explain techniques to increase communication and collaboration
- Formulate a plan for testing-related discussions with patients and encourage participation in treatment planning
FACULTY
Tim Cannon, MD
Sheridan Director, Molecular Tumor Board
Co-director of the Gastrointestinal Cancer Program
Inova Schar Cancer Institute
Fairfax, VA
Philip A. Philip, MD, PhD
Professor of Oncology
Pharmacy Director
GI and Neuroendocrine Oncology Karmanos Cancer Institute
Wayne State University
Detroit, MI
PLANNING COMMITTEE
Tim Cannon, MD
Sheridan Director, Molecular Tumor Board
Co-director of the Gastrointestinal Cancer Program
Inova Schar Cancer Institute
Fairfax, VA
Wei Jiang, MD, PhD
Associate Professor
Director, Translational Research/Pathology Shared Resource of Sidney Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, PA
Philip A. Philip, MD, PhD
Professor of Oncology
Pharmacy Director
GI and Neuroendocrine Oncology Karmanos Cancer Institute
Wayne State University
Detroit, MI
Frank dela Rama, RN, MS, AOCNS
Clinical Nurse Specialist
Oncology/Genomics
Sutter Health, Palo Alto Foundation
Mountain View, CA
Antonia Sepulveda, MD, PhD
Department of Pathology
Ralph E. Lowey Professor of Oncology
George Washington University School of Medicine and Health Sciences
Washington, D.C.
Manish Shah, MD
Chief, Solid Tumor Oncology
Weill Cornell Medicine
New York, NY
Benjamin Swanson, MD, PhD
Associate Professor
Associate Director
Gastrointestinal Pathology Fellowship
University of Nebraska Medical Center
Omaha, NE
Theodore Bruno, MD
Chief Medical Officer
The France Foundation
Old Lyme, CT
ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by The France Foundation and Association of Community Cancer Centers. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CREDIT DESIGNATION
Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
The France Foundation designates this activity for 1.0 nursing contact hour.
The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until February 27, 2024. PAs should only claim credit commensurate with the extent of their participation.
All other healthcare professionals completing this course will be issued a statement of participation.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) and International Society on Thrombosis and Haemostasis (ISTH) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF and ISTH resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.
Furthermore, TFF and ISTH seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ISTH are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.
Disclosures
The following financial relationships have been disclosed:
|
Name and Affiliation |
Role in Activity |
Name of Commercial Entity |
Nature of Relationship(s) |
Mechanism(s) implemented to resolve conflict of interest appropriate to role(s) in the activity |
|
Amanda Noe |
TFF Staff |
No relevant financial relationships |
NA |
NA |
|
Antonia Sepulveda, MD, PhD |
Planning Committee, Faculty |
1. Association of Community Cancer Centers, Caris Life Sciences |
1. Non-CE consulting |
The financial relationship with Caris Life Sciences ended in November 2022 All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee member Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning |
Ben Swanson, MD, PhD |
Planning Committee, Faculty |
1. Cogen Bioscience |
1. Non-CE consulting, owns stock of the publicly held commercial entity |
All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee member
Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning |
|
Frank dela Rama, RN, MS, AOCNS, AGN-BC |
Planning Committee, Faculty |
No relevant financial disclosures |
NA |
NA |
|
Heather Tarbox, MPH |
TFF Staff |
No relevant financial relationships |
NA |
NA |
|
Manish Shah, MD |
Planning Committee Member, Faculty |
1.Bristol-Meyers Squibb, Oncolys Biopharma |
1. Contract Research |
All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee member
Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning |
|
Megan Stephan, PhD |
Content Reviewer |
1. Foundation Medicine |
1. Salary or Employment Relationship |
Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning |
|
Philip Philip, MD |
Planning Committee Member, Faculty |
1. Bayer, Guardant, Incyte, Ipsen, Merck, Novocure, Pfizer, Rafael, Seagen 2.Daiichi, Incyte, Merck 3. AstraZeneca, Bayer, BMS, Incyte, Karyopharm, Novocure, Rafael, Servier |
1. Non-CE Consulting 2. Non-CE Speakers Bureau 3. Contract Research |
All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee member
Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning |
|
Regina Gibson-Burtnik |
ACCC staff |
No relevant financial disclosures |
NA |
NA |
|
Sarah Bingel-McKillips |
TFF Staff |
No relevant financial disclosures |
NA |
NA |
|
Ted Bruno, MD |
Planning Committee, TFF Content Reviewer |
No relevant financial disclosures |
NA |
NA |
|
Timothy Cannon, MD |
Planning Committee, Faculty |
No relevant financial disclosures |
NA |
NA |
|
Wei Jiang, MD, PhD |
Planning Committee, Faculty |
No relevant financial disclosures |
NA |
NA |
TFF and ACCC require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ACCC do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
This activity is supported by an educational grant from Pfizer.
The France Foundation and Association of Community Cancer Centers present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and Association of Community Cancer Centers and the commercial supporter(s) assume no liability for the information herein.
Copyright © 2023 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
- The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
- Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The France Foundation's prior written permission
The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
Additional information regarding The France Foundation’s Privacy Policy can be viewed at https://www.francefoundation.com/privacy.
Topic: Metastatic colorectal cancer
Accreditation Type:
Physicians—maximum of 1.0 AMA PRA Category 1 Credit(s)™
Nurses—1.0 contact hours of nursing continuing professional development credit
Physician Assistants—1.0 AAPA Category 1 CME credits
Accreditor: The France Foundation
Activity Dates: March 31, 2023 — March 30, 2024
Estimated Time to Complete Activity: 60 Minutes
CONTACT INFORMATION
METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Participate in the CME/CE activity.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- You will receive an email with a link to download your CME/CE certificate following the activity.
